MiNK Therapeutics to Present iNKT Cell Data at SITC 2024

NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a biopharmaceutical company at the clinical stage, is making significant advancements in the field of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies aimed at treating cancer and other immune-mediated diseases. The company recently announced it will present two posters at the Society for Immunotherapy of Cancer’s (SITC) 29th Annual Meeting, taking place from November 6-10, 2024, in Houston, Texas. These presentations will highlight new preclinical findings from their iNKT cell programs, agenT-797 and PRAME-TCR.

The first presentation, titled "AgenT-797 cell therapy can be combined with next-generation immune checkpoint inhibitors (ICI) and/or bi-specific engagers to improve anticancer response," is scheduled for Friday, November 8th. This presentation will showcase how agenT-797, when used in combination with contemporary immune checkpoint inhibitors and bi-specific engagers, can enhance the body's anticancer response. The abstract number for this presentation is 753.

The second poster, titled "PRAME-TCR iNKT cell therapy: Opportunity for best-in-class off-the-shelf solid tumor therapy targeting PRAME," will be presented on Saturday, November 9th. The abstract number for this session is 374. This presentation will discuss the potential of PRAME-TCR iNKT cell therapy to become a leading off-the-shelf treatment option for solid tumors by effectively targeting PRAME.

MiNK Therapeutics is known for its innovative work in the development and commercialization of allogeneic iNKT cell therapies. These therapies involve both native and next-generation engineered iNKT cells, which are designed to be manufactured on a large scale and delivered off-the-shelf. This approach aims to provide reproducible and scalable treatment options for patients.

Headquartered in New York, NY, MiNK Therapeutics is committed to advancing its pipeline of iNKT programs, which it believes could revolutionize cancer treatment and other immune-mediated conditions. The company's platform focuses on creating scalable and reproducible manufacturing processes to ensure that these therapies can be readily available for clinical use.

MiNK Therapeutics emphasizes the importance of its upcoming presentations at the SITC Annual Meeting as they will provide valuable insights into the preclinical data supporting their iNKT cell programs. The company encourages interested parties to attend the sessions to learn more about their innovative therapies and the potential impact they may have on cancer treatment.

The company regularly updates these channels with important information for investors and the general public.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!